Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 7/20 | 0.44 |
| ▸ | ADH1C | P00326 | 4/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982330 | 0.79 | ADH1B (0.39) | ADH1AADH1CADH1BMAPTTSHR | |
| SCHEMBL7274112 | 0.77 | ADH1A (0.38) | ADH1AADH1CADH1BTSHR | |
| SCHEMBL3285529 | 0.77 | ADH1A (0.38) | ADH1AADH1CADH1BTSHR | |
| SCHEMBL2338202 | 0.77 | ADH1B (0.38) | ADH1AADH1CADH1BMAPT | |
| SCHEMBL3285531 | 0.75 | ADH1C (0.35) | ADH1AADH1CADH1BTSHR | |
| SCHEMBL5850034 | 0.74 | ALDH1A1 (0.37) | ADH1AADH1CADH1BMAPT | |
| SCHEMBL8759979 | 0.73 | CTSL (0.37) | ADH1AADH1CADH1BTSHR | |
| SCHEMBL3671338 | 0.73 | ADH1B (0.33) | ADH1AADH1CADH1B | |
| SCHEMBL3671340 | 0.73 | ADH1B (0.33) | ADH1AADH1CADH1B | |
| SCHEMBL4975535 | 0.72 | ALDH1A1 (0.34) | ADH1AADH1CADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-7030262-B2 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBOTT LABORATORIES (US) | 2006-04-18 | — | — | US | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | ABBVIE INC. | 2004-06-24 | — | — | US | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | ADH1A 1608/4885ADH1C 1634/4885ADH1B 1163/4885 |
| US-20040122098-A1 | 3-Amino-2-hydroxyalkanoic acids and their prodrugs | HDGF, HCAR2, HCAR3 | ADH1A 152/4885ADH1C 378/4885ADH1B 482/4885 |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ADH1A 2553/4885ADH1C 2391/4885ADH1B 1098/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | ADH1A 2553/4885ADH1C 2391/4885ADH1B 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.